192 related articles for article (PubMed ID: 12815006)
1. Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men.
Allen NE; Reichardt JK; Nguyen H; Key TJ
Cancer Epidemiol Biomarkers Prev; 2003 Jun; 12(6):578-81. PubMed ID: 12815006
[TBL] [Abstract][Full Text] [Related]
2. The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men.
Allen NE; Forrest MS; Key TJ
Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):185-9. PubMed ID: 11303586
[TBL] [Abstract][Full Text] [Related]
3. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
Hsing AW; Chen C; Chokkalingam AP; Gao YT; Dightman DA; Nguyen HT; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Stanczyk FZ; Reichardt JK
Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1077-82. PubMed ID: 11588134
[TBL] [Abstract][Full Text] [Related]
4. 5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia.
Hayes VM; Severi G; Padilla EJ; Morris HA; Tilley WD; Southey MC; English DR; Sutherland RL; Hopper JL; Boyle P; Giles GG
Int J Cancer; 2007 Feb; 120(4):776-80. PubMed ID: 17136762
[TBL] [Abstract][Full Text] [Related]
5. Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer.
Lamharzi N; Johnson MM; Goodman G; Etzioni R; Weiss NS; Dightman DA; Barnett M; DiTommaso D; Chen C
Int J Cancer; 2003 Jul; 105(4):480-3. PubMed ID: 12712437
[TBL] [Abstract][Full Text] [Related]
6. The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.
Giwercman YL; Abrahamsson PA; Giwercman A; Gadaleanu V; Ahlgren G
Eur Urol; 2005 Oct; 48(4):679-85. PubMed ID: 16039774
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer.
Li X; Huang Y; Fu X; Chen C; Zhang D; Yan L; Xie Y; Mao Y; Li Y
Mutagenesis; 2011 May; 26(3):371-83. PubMed ID: 21177315
[TBL] [Abstract][Full Text] [Related]
8. Importance of 5α-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer.
Lévesque É; Laverdière I; Lacombe L; Caron P; Rouleau M; Turcotte V; Têtu B; Fradet Y; Guillemette C
Clin Cancer Res; 2014 Feb; 20(3):576-84. PubMed ID: 24277450
[TBL] [Abstract][Full Text] [Related]
9. Polymorphism of the SRD5A2 gene and the risk of prostate cancer.
Dušenka R; Tomaškin R; Kliment J; Dobrota D; Dušenková S; Vilčková M; Sivoňová MK
Mol Med Rep; 2014 Dec; 10(6):3151-6. PubMed ID: 25310105
[TBL] [Abstract][Full Text] [Related]
10. Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk.
Kakinuma H; Tsuchiya N; Habuchi T; Ohyama C; Matsuura S; Wang L; Nakamura A; Kato T
Prostate Cancer Prostatic Dis; 2004; 7(4):333-7. PubMed ID: 15477877
[TBL] [Abstract][Full Text] [Related]
11. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population.
Yamada Y; Watanabe M; Murata M; Yamanaka M; Kubota Y; Ito H; Katoh T; Kawamura J; Yatani R; Shiraishi T
Int J Cancer; 2001 Jun; 92(5):683-6. PubMed ID: 11340572
[TBL] [Abstract][Full Text] [Related]
12. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
[TBL] [Abstract][Full Text] [Related]
13. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA.
Makridakis NM; Ross RK; Pike MC; Crocitto LE; Kolonel LN; Pearce CL; Henderson BE; Reichardt JK
Lancet; 1999 Sep; 354(9183):975-8. PubMed ID: 10501358
[TBL] [Abstract][Full Text] [Related]
14. 5alpha-reductase 2 polymorphisms as risk factors in prostate cancer.
Söderström T; Wadelius M; Andersson SO; Johansson JE; Johansson S; Granath F; Rane A
Pharmacogenetics; 2002 Jun; 12(4):307-12. PubMed ID: 12042668
[TBL] [Abstract][Full Text] [Related]
15. Molecular Analysis of the SRD5A1 and SRD5A2 Genes in Patients with Benign Prostatic Hyperplasia with Regard to Metabolic Parameters and Selected Hormone Levels.
Rył A; Rotter I; Grzywacz A; Małecka I; Skonieczna-Żydecka K; Grzesiak K; Słojewski M; Szylińska A; Sipak-Szmigiel O; Piasecka M; Walczakiewicz K; Laszczyńska M
Int J Environ Res Public Health; 2017 Oct; 14(11):. PubMed ID: 29084161
[No Abstract] [Full Text] [Related]
16. Single-nucleotide polymorphism in the 5-α-reductase gene (SRD5A2) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors.
Boer H; Westerink NL; Altena R; Nuver J; Dijck-Brouwer DAJ; van Faassen M; Klont F; Kema IP; Lefrandt JD; Zwart N; Boezen HM; Smit AJ; Meijer C; Gietema JA
Eur J Cancer; 2016 Feb; 54():104-111. PubMed ID: 26751392
[TBL] [Abstract][Full Text] [Related]
17. No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned.
Pearce CL; Van Den Berg DJ; Makridakis N; Reichardt JK; Ross RK; Pike MC; Kolonel LN; Henderson BE
Hum Mol Genet; 2008 Aug; 17(16):2456-61. PubMed ID: 18469342
[TBL] [Abstract][Full Text] [Related]
18. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR.
Cicek MS; Conti DV; Curran A; Neville PJ; Paris PL; Casey G; Witte JS
Prostate; 2004 Apr; 59(1):69-76. PubMed ID: 14991867
[TBL] [Abstract][Full Text] [Related]
19. SRD5A2 gene polymorphisms affect the risk of breast cancer.
Francis A; Sarkar S; Pooja S; Surekha D; Rao DR; Rao L; Ramachandra L; Vishnupriya S; Satyamoorthy K; Thangaraj K; Rajender S
Breast; 2014 Apr; 23(2):137-41. PubMed ID: 24365257
[TBL] [Abstract][Full Text] [Related]
20. The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism.
Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):191-6. PubMed ID: 26857022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]